$16.4
+0.2
(+1.23%)▲
4.12%
Downside
Day's Volatility :5.04%
Upside
0.97%
65.65%
Downside
52 Weeks Volatility :78.62%
Upside
37.76%
Period | Newamsterdam Pharma Company Nv | Index (Russel 2000) |
---|---|---|
3 Months | -15.03% | 0.0% |
6 Months | -21.61% | 0.0% |
1 Year | 62.54% | 0.0% |
3 Years | 58.45% | -22.3% |
Market Capitalization | 1.5B |
Book Value | $4.3 |
Earnings Per Share (EPS) | -2.62 |
Wall Street Target Price | 37.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -2306.93% |
Return On Assets TTM | -27.15% |
Return On Equity TTM | -54.08% |
Revenue TTM | 7.4M |
Revenue Per Share TTM | 0.09 |
Quarterly Revenue Growth YOY | 32.7% |
Gross Profit TTM | 0.0 |
EBITDA | -208.6M |
Diluted Eps TTM | -2.62 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.44 |
EPS Estimate Next Year | -1.74 |
EPS Estimate Current Quarter | -0.58 |
EPS Estimate Next Quarter | -0.51 |
What analysts predicted
Upside of 125.61%
Sell
Neutral
Buy
Newamsterdam Pharma Company Nv is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Newamsterdam Pharma Company Nv | 4.73% | -21.61% | 62.54% | 58.45% | 58.45% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Newamsterdam Pharma Company Nv | 30.14 | NA | NA | -2.44 | -0.54 | -0.27 | NA | 4.3 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Newamsterdam Pharma Company Nv | Buy | $1.5B | 58.45% | 30.14 | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Newamsterdam Pharma Company Nv
Revenue is up for the last 2 quarters, 1.40M → 2.27M (in $), with an average increase of 38.5% per quarter
Netprofit is up for the last 2 quarters, -93.76M → -39.00M (in $), with an average increase of 140.4% per quarter
FCPM III SERVICES BV
Bain Capital Life Sciences Investors, LLC
RA Capital Management, LLC
Viking Global Investors LP
Medicxi Ventures Management (Jersey) Ltd
Cormorant Asset Management, LLC
Organization | Newamsterdam Pharma Company Nv |
Employees | 57 |
CEO | Dr. Michael Harvey Davidson FACC, Facp., M.D. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$16.40
+1.23%
Keyarch Acquisition Corp
$16.40
+1.23%
Connexa Sports Technologies Inc
$16.40
+1.23%
Us Value Etf
$16.40
+1.23%
First Wave Biopharma Inc
$16.40
+1.23%
Global X Msci Next Emerging
$16.40
+1.23%
Fat Projects Acquisition Corp
$16.40
+1.23%
Capital Link Global Fintech
$16.40
+1.23%
Applied Uv Inc
$16.40
+1.23%